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The treatment of coronary at6erosclerosis requires an under.
of the p dhophyslology of plaque rupture
. The rupture of
llpiddaden, ma~crophaga-rich plaques Initiates unstable angina,
acute myowdlat kA ction ead sudden cardiac death . plaque
rupture occurs when the rlrcumferentlal tension on a plaque
exceeds ib tensile strrength, an event that cannot be predicted by
coronary anglography . The incidence of plaque rupture appears
to be reduced In patients receiving cholesterol-lowering therapy,
beta-adreaergle blocking agents and, possibly, anglotensin-
converting enzyme Inhibitors and antioxidants. Not all ruptured
coronary plaques produce an acute coronary syndrome. The
consequences of plaque rupture depend a the extent of thrombus
fbrasaton over the fissured plaque. This is determined by How
Coronary atherosclerotic plaques vary greatly in their sta-
bility . In western society coronary atherosclerosis is ubiqui-
tous, albeit predominantly asymptomatic . When plaques
limit coronary flow, patients develop angina, which may be
stable for years. Conversely, patients may suddenly develop
an acute coronary ischemic syndrome . The coronary event
that precipitates these syndromes is plaque rupture (1-11). If
plaque progression, unstable angina, acute myocardial in-
farction and sudden cardiac death are to be prevented,
vulnerable plaque must be identified and stabilized . Re-
cently, efforts have been made to treat coronary atheroscle-
rosis with aggressive lipid-lowering therapies (12-19) . Al-
though small degrees of regression have been achieved in a
minority of patients, a more considerable reduction in the
incidence of cardiac events has been achieved . This indi-
cates that the stabilization of plaque is possible . The devel-
opment of new cardiac diagnostic techniques and recent
advances in molecular and cellular biology have opened a
window of opportunity to study the factors influencing
plaque stability . The stabilization of vulnerable plaque
should be the new aim of the treatment of coronary athero-
sclerosis . This paradigm shift will allow a preventative
approach to acute myocardial ischemia . The purpose of this
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characteristics within the vessel as well as the activity of the
thrmbosk and Abrinolytic systems . Recent advances In cardio-
vascular molecular biology, coronary diagnostic techniques sod
cardiac therapeutics have opened windows of opportunity to study
and modify the factors leading to plaque rupture. The lead
modification of gene expression to alter plaque composition and to
elucidate and subsequently Inhibit the prothrombottc and fibrino-
lytic defects that promote coronary thrombosis may, in future,
prevent plaque rupture and Its consequences . The application of
such a concerted Interdisciplinary approach promises a paradigm
shift In the management of coronary artery disease toward the
prevention of plaque rupture and its sequelae .
(J Am Cog Cordial 1993 ;22:1228-41)
review is to identify some of the factors that lead to coronary
atherosclerotic plaque rupture and to consider how plaque
can be stabilized and rendered quiescent .
Development of Atherosclerosiis
It is beyond the scope of this review to consider in detail
the pathogenesis and etiology of atherosclerosis, which can
be found in several recent reviews (20--22). However, a
framework will be provided to allow a better understanding
of the etiology and mechanism of plaque rupture .
The fatty streak. The fatty streak is the earliest lesion of
atherosclerosis (23). This intimal lesion contains foam cells
and a small number of T lymphocytes . Foam cells are
predominantly derived from tissue macrophages and io a
lesser degree from smooth muscle cells that accumulate
large amounts of intracellular lipid . This cholesterol is pri-
marily derived from oxidized low density lipoproteins
(LDLs) (21). These are cytotoxic and chemotactic particles
that are taken up by the macrophage scavenger receptor
(24) . The factors that initiate the recruitment of monocytes
and macrophages into atherosclerotic lesions are only par-
tially understood. Vascular endothelial cells and smooth
muscle cells produce several chemotactic cytokines . Re-
cently, a potent chemoattractant, monocyte chemotactic
protein 1, was isolated and found to be secreted by vascular
smooth muscle cells and endothelial cells in vitro (25). It was
shown by in situ hybridization that monocyte chemotactic
protein I is present in the intima of macrophage-rich athero-
sclerotic lesions and that it is also present in macrophage-
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derived foam cells (26) . Monocyte chemotactic protein 1
secretion by smooth muscle and endothelial cells is induced
in vitro by oxidized LDL and therefore may be the messen-
ger that mediates the chemotactic properties of oxidized
LDL (27,28).
Mature Plaque . Fatty streaks may progress to mature
plaques. Platelets adhere to the lesion and secrete growth
factors, including platelet-derived growth factor, epidermal
growth factor, transforming growth factor-beta and so-
matomedin C (20,29) . These growth factors initiate smooth
muscle cell migration from the media to the intima and
stimulate the production of collagen types I and III, elastin
and glycoproteins . These proteins provide the connective
tissue matrix of the plaque and give the plaque its structural
strength. Extracellular cholesterol crystals and cholesterol
esters derived directly from LDL or extruded by decaying
foam cells accumulate within this matrix (30) . The lipid and
connective tissue matrix are covered by a flbromuscular
cap consisting of smooth muscle cells and collagen and a
single layer of endothelial cells (31) . The composition of
nonruptured atheromatous plaques is highly variable (32).
Plaques causing severe stenoses tend to have a higher
fibrous and lower lipid content than those producing less
severe lesions (32-34) . The factors controlling plaque com-
position are not understood, but plaque lipid content de-
creases after a reduction in serum cholesterol levels in
animal models (35) . Cholesterol is constantly being trans-
ported in and out of the plaque . Cholesterol enters the
plaque in the form of LDL and lipoprotein (a), which is
similar to LDL but contains an additional apolipoprotein,
apolipoprotein (a) (32-34,36) . Lipoprotein (a) has been
shown to be an independent risk factor for coronary artery
disease (37) . High density lipoproteins (HDL) remove cho-
lesterol from foam cells, reenter the circulation and transfer
it to LDLs and very low density lipoprotein. Cholesterol is
then transported to the liver. Epidemiologic studies have
shown that the incidence of myocardial infarction is directly
related to the serum levels of LDLs and inversely to the
levels of HDL (38) .
Mechanisms of Acute Ischemic Syndromes
Acute coronary ischemic syndromes are caused by cor-
onary thrombi, as confirmed by multiple clinical and autopsy
studies (1,2,39-42). Intracoronary thrombus has also been
found in 7090 of cases of sudden cardiac death (7,43) .
Coronary thrombosis occurs only in arteries containing
atherosclerosis (44). The rupture of the surface of an athero-
sclerotic plaque initiates coronary thrombosis (1-11). Davies
and Thomas (2) found ruptured atherosclerotic plaques
underlying 103 (90%) of 115 episodes of coronary thrombosis
that they observed in 74 patients dying of ischemic heart
diseps, , .
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Figure 1. Angiogram of the right coronary artery in the left anterior
oblique (A), and right anterior oblique (B) projections demonstrating
a ruptured plaque, with associated thrombus formation in the
mid-right coronary artery .
Coronary Angiography and Plaque Rupture
Coronary angiography can detect some ruptured plaques .
When apparent by angiography, these plaques are typically
eccentric, hazy convex lesions with overhanging, irregular
margins (8,11,45,46) (Fig . 1). However, coronary angiogra-
phy does not predict the likelihood of an intact plaque
rupturing (47-51). In two thirds of patients presenting with
an acute ischemic syndrome, the culprit lesion was thought
to be insignificant on a previous coronary angiogram (47) .
Myocardial infarction is due to the previously most severe
coronary stenosis in only one third of cases (50,51) . Giroud
et al. (51) found that 78% of segments responsible for
myocardial infarction were not significantly stenosed
(<50%) on a previous angiogram . Ambrose et al . (47) also
showed that the average degree of stenosis of lesions subse-
quently progressing to myocardial infarction is 48%
.
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Figure 3. 1Pathalog(c specimen of a ruptured coronary atheroscle-
rotic plaque with associated intraplaque and intralumen thrombus
(black) . The lumen contains contrast material Injected postmortem
(white) . Reprinted, with permission, from Falk E. Morphologic
features of stable and unstable plaques underlying acute ischemic
syndromes, Am J Cardiol 1959 ;63 : I15E.
Morphology of Ruptured Plaques
Three basic features of a ruptured atheromatous plaque
have been described . These are intimal rupture . intimal
hemorrhage and intralumen thrombus (Fig . 2) (1-3).
IMlami rupture. Ruptured plaques have a high lipid and
macrophage content (5,6,30,52) . They contain more extra-
cellular lipid and less collagen, smooth muscle cells and
calcium than intact plaques (30,34) (Tables 1 and 2) . Fissures
tend to occur at the margins of plaques where caps are
necrotic, very thin and extensively infiltrated by macro-
phages (1,2,44,53). Richardson et al. (53) demonstrated that
plaques rupture at the junction of the plaque fibrous cap and
the adjacent normal tissue in 64% of cases .
Intraplaque hemorrhage. Intracoronary thrombus is seen
in 81% of ruptured plaques (52). Barger and co-workers
(54,55) suggested that these intimal hemorrhages may be due
to rupture of coronary vasa vasorum and that this may be the
mechanism of plaque rupture. This proposed mechanism has
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Table 1. Biochemical Analysis of Protein and Extracellular Lipid
Content of Ulcerated and Intact Human Aortic Plaque Caps
(% plaque volume)
*p < 0
.05,
tp < 0.001 . Values presented am mean value ± SEM .
Modified, with permission, from Davies et al . (30) .
been strongly disputed by Constantinides (44), who found
that intraplaque hemorrhages usually develop in avascular
regions of plaque and are due to the entry of lumen blood
into the plaque.
Intraceronary thrombus formation. Plaque rupture ex-
poses the highly thrombogenic subendothelial components
of the arterial wall to the circulation (56) . This leads to
platelet adhesion, activation and the secretion of platelet
granules containing coagulation, growth and hemostatic fac-
tors (56-58). Platelet glycoprotein Ia binds directly to sub-
endothelial collagen (59), and glycoprotein lb combines with
subendothelial von Willebrand factor (56) . The activated
platelets also express the glycoprotein llb/Illa membrane
receptor complex that binds circulating fibrinogen, von
Willebrand factor and fibrinonectin, thus linking the plate-
lets. The coagulation cascade is activated by the damaged
subendothelium (intrinsic coagulation pathway) and by the
exposure of tissue factor (extrinsic coagulation pathway)
(56,59,60). These pathways result in the formation of fibrin,
which consolidates thrombus formation.
Consequences of Plaque Rupture
Not all ruptured plaques produce an acute ischemic
syndrome. The consequences of plaque rupture depend on
the extent of coronary thrombus formation (Fig . 3) . Unstable
angina, acute myocardial infarction or sudden cardiac death
will occur only if coronary flow is reduced and collaterP' flow
is inadequate (61) . Intraplaque hemorrhage may produce
rapid asymptomatic plaque progression regardless of
whether coronary flow is limited (62) . This explains the
Table 2. Cellular Content of Ulcerated and Intact Human Aortic
Plaque Caps
*p < 0
.001 . Values are presented as mean value (SEM). MO = mono-
cytes; SMC = smooth muscle cells . Modified, with permission, from Davies
et al. (30) .
Ulcerated Plaques
(n = 24)
Nonulcerated Plaques
(n = 31)
Total protein (% dry weight) 54.8 :t 1
.2 57 .2 ± 2 .2
Collagen
35 .4 ± 8.4 56 .8 ± 1 .4*
Elastin
0.87 ± 0.87 1 .17 ± 0.31
Glycosoaminoglycan 0.9 ± 0.20
1 .9 ± 0.2*
Extracellular lipid
54.9 ± 3.8 22 .1 ± 2.4t
Ulcerated
(n =
Plaques Nonulcerated
24) (n
Plaques
= 31)
Density of SMC
65.2 ± 13 .!
174
.0 ± 11 .9*
Density of MO 122 .1 ± 13.3 62 .2 ± 8.8*
SMCIMO ratio 1 .2 5.8*
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Vulnerable
Plaque
Figure 3. Rupture of a vulnerable atherosclerotic plaque results in
an asymptomatic healed fissure, a mural thrombus
or an occlusive
thrombus. Modified, with permission of the American Heart Asso-
ciation, Inc ., from Davies MJ (40) .
stepwise rather than linear increase in plaque severity dem-
onstrated by serial coronary angiography (48,63). Asymp-
tomatic coronary plaque rupture has been found in 8 .7% of
cases of noncardiac death (43) . This incidence increases in
diabetic patients and in subjects with a history of hyperten-
sion or myocardial infarction.
The extent of coronary thrombus formation after plaque
rupture depends on the depth of the intimal fissure . Deep
intimal rupture exposes the arterial media, which is more
thrombogenic than the intima exposed by superficial tears .
Deep fissures are therefore more likely to produce occlusive
thrombus (64). The severity of the underlying stenosis also
may determine the extent of coronary thrombus formation .
Autopsy studies have also shown that occlusive thrombus is
seen more frequently over severe underlying stenoses . At
autopsy, Falk (65) found occlusive thrombus in 61% of cases
where the underlying atherosclerotic plaque reduced the
vessel lumen by >75% but only in 3% of cases where the
plaque occluded <75% of the lumen . However, the relation
between lesion severity and the extent of thrombus forma-
tion is uncertain because coronary angiography often dem-
onstrates a mild residual stenosis after thrombolytic therapy
for acute myocardial infarction (66-69) .
The occurrence of myocardial infarction shows a diurnal
variation (70) that is prevented by aspirin therapy (71) .
Platelet aggregation is increased (72-74) and fibrinolytic
activity decreased (75,76) in the morning . Thus, the conse-
quences of plaque rupture are influenced by the activity of
the coagulation and thrombotic systems (77,78) . A continu-
ous prothrombotic state may predispose some, patients to
myocardial infarction once plaque rupture has occurred .
Elevated concentrations of fibrinogen and Factor VII are
independently associated with increased cardiac mortality
(79,80). High levels of circulating von Willebrand factor have
also been shown to be independently associated with rein-
farction and death (81). Cardiovascular mortality is greater
MACISAAC ET AL
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in patients with thrombocytosis and increased platelet aggre-
gation rates (82,83) .
Impaired fibrinolysis may also potentiate thrombus for-
mation. Fibrinolysis is mediated by plasmin, which is pro-
duced from plasminogen (84) . Plasminogen is activated by
tissue plasminogen activator (t-PA) . Tissue olasminogen
activator is rapidly inactivated by plasminogen activator
inhibitor (84). Global fibrinolytic activity does not appear to
predict the risk of either first or recurrent myocardial infarc-
tion (79,84-87) . However, high levels of plasminogen acti-
vator inhibitor and low levels of t-PA are associated with
increased risk of recurrent myocardial infarction (84,86,87)
and myocardial infarction associated with angiographically
normal coronary arteries (88) . Lipoprotein (a) may also
impair fibrinolysis . Lipoprotein (a) contains apolipoprotein
(a), which has considerable amino acid sequence homology
with plasminogen (89-91), but because of a crucial substitu-
tion of serine for arginint., lipoprotein (a) has no enzymatic
activity (91) . Lipoprotein (a) therefore competes with serum
plasminogen for binding sites and inhibits the activation of
plasminogen by t-PA, thus serving as a procoagulant . There-
fore lipoprotein (a) is not only associated with atherogenesis
but also promotes thrombogenesis by inhibiting fibrinolysis
(92).
Trigger Events and Plaque Rupture
Half of the patients with a myocardial infarction associate
it with a trigger event (93). The most frequently reported of
these trigger events are emotional stress and physical activ-
ity (93-98) . Several reports have temporally related myocar-
dial infarction to strenuous physical activity, including vig-
orous sports and exercise stress testing (94,95,98) . In these
patients, postinfarction angiography has usually demon-
strated a ruptured plaque even in some patients who had
angiographically normal coronary arteries before infarction
(95). This observation emphasizes the potential importance
of mild plaques not detected by coronary angiography .
Physical activity may produce a pressure surge within the
coronary artery lumen. A sudden surge of arterial pressure
in the presence of endothelial damage can produce plaque
rupture in animal models (1) . Case reports indicate that
emotional stress can also provoke plaque rupture (96). The
incidence of acute myocardial infarction increased in Israel
during the Scud missile attacks of the 1991 Persian Gulf War,
apparently because of increased emotional stress (97). How-
ever, a causal link between these trigger events and myocar-
dial infarction has not been established . Both emotional and
physical stress may contribute to myocardial infarction by
increasing blood pressure and by inducing coronary vaso-
spasm. Vasospasm can produce endothelial damage (99-
102), and patients with vasospasm inducible at cardiac
catheterization are more likely to have subsequent myocar-
dial infarction (103) . Constantinides and Lawder (104) sug-
gested from an experimental model that vasoconstriction
may produce intracoronary thrombus in the presence of a
1232
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thrombotic tendency . Vasospasm may also have produced
the "volcanolike eruptions" of lipid from ruptured plaques
described by Lin et al . (100)
. All of these observations
suggest that vasospasm plays a role in the pathogenesis of
plaque rupture (102-106)
.
Mechanics of Plaque Rupture
Plaque rupture will occur when the forces acting on a
plaque exceed its tensile strength
. To understand this pro-
cess, it is worthwhile to review the mechanical properties of
the arterial wall and the origin of the hemodynamic forces
that act on it .
Material properties. Two key concepts are used to define
the structural properties of any material
: stress and strain .
Stress is the amount of force per unit area acting across a
block of tissue, whereas strain is the amount of deforina
.
don induced in that block by the stress . For a 1-cm cube
of tissue with 10,000 dynes (glcm per s2) applied across
it, the applied stress is 10,000 dynes/cm2, or 7
.5 mm Hg
(1 mm Hg = 1,333 dyneslcm2)
. Strain is the amount of
deformation in a material, normalized to its length . If a 1-cm
cube is stretched by 1 mm, it has a strain of 0 .1, or 10%.
Characterizing the elastic strength (or stiffness) of the mate-
rial is Young's modulus (E), given by the ratio of an applied
stress to an observed strain. For the given example, E _
7.5 mm Hg/0.1, or 75 mm Hg.
An isotropic material is one with identical stiffness in all
directions . Arterial structures, however, are much more
complex. First, they are distinctly anisotropic, being consid-
erably stiffer in their axial and circumferential directions
than in the radial direction (as much as a 10-fold difference) .
Second, the forces acting on a material may be sliding or
shear rather than tensile, with resistance to these forces
characterised by G, the shear modules. The presence of
parallel collagen fibers makes the arterial wall considerably
stiller to tensile forces directed along the fibers than to shear
forces, tending to make the fibers slide past each other.
Third, the elastic properties of most biologic materials are
nonlinear, becoming stiffer (i .e., rising Young's modulus)
with increasing degrees of strain . Finally, plaque stiffness
also increases with the frequency of the applied stress . Lee
et al. (107) analyzed aortic atherosclerotic plaque under
dynamic stress . At a frequency of 1 Hz, cellular plaques
showed an average stiffness of 3,800 mm Hg, whereas E
averaged 6,800 mm Hg for hypocellular plaques and
16,500 mm Hg for calcific plaques . For each plaque type,
stiffness increased approximately 15% as stimulus frequency
increased from 0.5 to 2.0 Hz .
Of* of arterial wall stress . The blood pressure inside
the artery exerts a radial force across the arterial wall as well
as a circumferential force, which must be counteracted by
tension within the wall to keep the vessel intact . This
circum ferential tension is described by the law of Laplace,
relating it to the intracavity pressure and lumen radius (Fig
.
4): t = p•r
, where t = wall tension (dyneslcm) ; r = vessel
teepar
per
h
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Figure 4. Circumferential tension on the fibrous cap of an athero-
sclerotic plaque containing a lipid pool (hatched area) is determined
by the law of Laplace . This relates tension (t) to the iutralumen
pressure (p) and the lumen radius (r)
. The mean circumferential
stress (a) on the fibrous cap is related to circumferential tension and
cap thickness (h) .
radius (cm); and p = intralumen pressure (dyneslcm2) . If the
wall thickness (h) of the artery is taken into account, then the
average circum erential wall stress (a) can be calculated as
a = p-r/h. Thus, larger diameter vessels, higher intraarterial
pressures and thinner arterial walls all lead to increased wall
stress (Fig . 4) . This may provide part of the explanation of
why moderate rather than severe atherosclerotic lesions are
more likely to rupture . For a given intracorona~ )' pressure,
the wall tension on a 50% stenosis is five time' natter thnh
that on a 90% stenosis . To the extent that the more severe
stenosis is associated with increased wall thickness, average
transmural wall stress is further reduced .
Walt stress with atheroselerosis. The foregoing discussion
• mean wall stress is relevant only for thin walls with
homogeneous omposition . For walls with heterogeneous
components (normal wall, fibrous and calcific plaques and
pools of lipid), focal concentrations of circumferential stress
may occur that aright well lead to plaque fissuring . Richard-
son et al. (53) used a finite-element computer model that
assigned different mechanical properties to the components
• the arterial wall to study the effects of plaque configura-
tion on the distribution of wall stress. Circumferential stress
in an artery is greatest at the arterial intima and falls across
the vessel wall . Local variations in tissue characteristics can
lead to dramatic alterations in stress distribution . Areas with
decreased load-hearing capabilities, such as a lipid pool,
resulted in increased stress elsewhere in the vessel wall . The
presence of an extracellular lipid pool in a plaque, extending
around >45% of the vessel circumference, increased stress
• the lateral edge of the plaque cap (Fig. 5), a frequent site
of plaque rupture (53) . Because the lipid pool has almost no
tensile strength, all of the stress that would normally be
borne by that region of the wall is displaced to the overlying
fibrous cap, and peak stress in the cap is critically related to
its thickness. Loree et al. (108) used finite element modeling
to demonstrate a fourfold increase in peak wall stress as the
plaque thickness was reduced from 250 to 50 um for a
constant 70% stenosis.
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Figure 5. Map showing the contours of circumferential stress in a
computer model of a 90° segment of a coronary artery with a lipid
pool (L) . The highest tensile circumferential stress (H) is on the cap
at the edge of the lipid pool, where contour lines lie close together .
Reproduced, with permission, from Richardson et al . (53) .
Plaque strength and rupture. Plaque rupture occurs when
the strain within the fibrous cap exceeds the deformability of
component material. The precise timing of plaque fracture is
quite complex. In calcific plaques, it may occur abruptly (as
in a piece of glass), whereas cellular plaques may show a
more gradual or ductile fracture . The strength of collagen,
elastin and other structural proteins may be reduced by the
effects of macrophage proteases (109,110) . Furthermore,
these proteases may lead to actual erosion of the fibrous cap
overlying a lipid pool, thus increasing the concentration of
wall stress at the same time that the ability of the cap to
resist deformation is reduced . Stromelysin, a metalloprotei-
nase capable of degrading most constituents of the extracel-
lular plaque matrix (110), has been demonstrated by in situ
hybridization and immunocytochemistry within macro-
phages in human atherosclerotic plaques (111) . Ruptured
plaques contain a higher concentration of macrophages than
do nonruptured plaques (109) . However, comparative quan-
tification of proteases in ruptured and stable plaques has not
been performed .
Fluid Dynamics and Atherosclerosis
The endothelium is constantly exposed to the influence of
passing blood, which may play important roles in both the
initiation of the atherosclerotic process as well as plaque
weakening and rupture. Among the fluid dynamics, concepts
important to these processes are shear stress, flow separa-
tion and turbulence .
Shear stress. Because of viscosity, blood velocity at the
vessel wall must be zero (112) . The rate at which the axial
velocity rises as one moves from the vessel wall toward the
center is termed the shear rate, dv/dr. This velocity gradient
causes a shear stress (T) on the endothelium, parallel to the
blood flow and proportional to viscosity JA: r = µ-dv/dr.
The magnitude of the wall shear rate depends on both the
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Figure 6. Velocity profile across a normal vessel (solid curve) and
within a 50% stenosis (dashed curve) . The increased velocities and
the flattening of the velocity profile within the stenosis result in
gi catly increased shear stress (r) . Shear stress = µ •dv/dr, where µ is
viscosity . See text for details .
velocity in the center of the vessel and the shape of the flow
profile. For fully developed laminar flow in an artery,
Poiseuille's law dictates that the velocity profile should be
parabolic in shape, for which the shear rate at the wall is
given quite simply by 2vdr, where vo is the centerline
velocity, and thus r = 2µvdr. Rewriting this in terms of flow
rate (Q = m 2vd2), we obtain r = 4µQ/m3.Thus, for regions
of fully developed laminar flow, the shear stress is inversely
proportional to the cube of the radius, and a small change in
the radius will produce a large change in the shear stress . In
reality, moreover, flow into a stenotic zone will increase T
even beyond that anticipated by the change in radius. This is
because acceleration of blood into a stenosis flattens the
velocity profile, leading to a much more rapi •i increase in
blood velocity adjacent to the vessel wall than parabolic flow
(Fig. 6). This flattened velocity profile results in a much
greater increase in shear stress than would be predicted from
the change in radius alone . Complicating the issue in vivo is
the fact that blood is a non-Newtonian fluid, with viscosity
decreasing at higher shear rates . This, along with the com-
pliant nature of the vessel wall, has been shown in vitro to
alter shear rates at the wall (113) .
The normal response of coronary arteries to increased
flow is to vasodilate (l 14) . The stimulus to this endothelium-
dependent vasodilation is thought to be increased sheu
stress . Increasing the vessel diameter counteracts the effects
of increased flow and reduces shear stress . This compensa-
tory mechanism does not occur in atherosclerotic segments
of coronary artery (115). Shear stress can produce endothe-
lial damage (101,116) . Whether this damage is sufficient to
initiate plaque rupture is unknown . However, if shear stress
was the major factor causing plaque rupture, then it would
be expected that those lesions with the highest shear stress
1234
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(i.e.,
those with high flow through a tight stenosis) would
rupture most frequently (117)
. As demonstrated by serial
angiographie studies (47,48,68,118,119), however, this does
not appear to be the case.
Flow separation . When flowing blood encounters a sud-
den increase in lumen diameter (as at the exit from a
stenosis), streamlines of flow lose attachment to the wall and
form a jet. Between the jet and the wall is a stagnant flow
region, where the velocity is low and may even be reversed
from the jet direction to form a recirculation zone (112).
Similar flow separation also occurs at abruptly branching
vessels. The abnormally low shear rate at the wall in such
regions may contribute to
the precipitation of blood proteins,
adherence of platelet and inflammatory cells and propagation
of thrombi after plaque rupture (112) . For example, intimal
thickness has been found in the carotid to be inversely
related to wall shear (120) .
Turbulent shear oft= . When the inertial forces present
within a flow field exceed the stabilizing viscous forces,
turbulence results. A measure of the tendency toward tur-
bulence is the Reynolds number, Re = pUL/ . , where U is a
characteristic velocity of the system (e .g., mean arterial
velocity), L is a characteristic linear dimension (e .g., vessel
diameter), and p and A are blood density (1 .05 glcm) and
viscosity (0.03 g/cm per s), respectively . In a smooth vessel,
turbulent transformation occurs at approximately Re
2,300 (e .g ., 130 cm/s in R 5-mm artery) but occurs more
readily (Re - 500) beyond abrupt stenoses (121) and in the
deceleration phase of pulsatile flow . Turbulence superim-
poses on the flow field a high frequency velocity fluctuation
equivalent to -25% of the mean velocity magnitude, which
results in an additional force on the endothelium . Loree et al .
(122), using a steady flow model, showed that turbulent jets
can produce high frequency pressure variations of up to
15 mm Hg distal to a 90% asymmetric stenosis .
It is tempting to hypothesize that the concordance of
shear and turbulent stresses plays a role in the rupture of
vulnerable plaque. It is clear that these hydrodynamic forces
by themselves are an order of magnitude smaller than the
stresses imposed on the plaque by the mean blood pressure
and the pulse pressure. The localization of early intimal
Lesions to specific regions around arterial branches indicates
a role of flow fields in the initiation of atherosclerosis (123),
but whether shear and turbulent forces are sufficient to
weaken the tensile strength of a mature fibrous cap, either by
direct physical abrasion or modulation of macrophage-borne
proteases, is unknown. It is clear that a complex interplay of
mechanical and
hydrodynamic forces impacts both the
strength of the
plaque and the stresses imposed on it and that
once circumferential stress on the cap exceeds its tensile
strength, plaque rupture must result .
Prevention of Plaque Rupture
Iatravascrdar ultrasound . Current efforts to prevent
acute ischemic syndromes have been limited by an inability
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to prospectively identify plaque vulnerable to rupture . The
development of intravascular ultrasound has allowed the
assessment of plaque morphology and composition (124-
128). Preliminary data suggest that intravascular ultrasound
can be used to differentiate ruptured from stable plaques
(129). Ruptured plaques have thinner intimal leading edges
and larger intimal sonolucent zones by ultrasound than do
stable plaques (Fig . 7). However, it remains to be seen
whether these plaque characteristics can be used to identify
regions of future rupture . The prospective identification of
vulnerable plaque would allow the appropriate application of
coronary interventions with the aim of reducing the inci-
dence of myocardial infarction . For example, markedly
sonolucent content of the arterial wall will most likely
indicate a rich lipid pool and the appropriate use of hypolip-
idemic therapy . In contrast, a dense, fibrocalcific lesion may
be especially unlikely to rupture . In the more distant future,
the application of nuclear magnetic resonance spectroscopy
may allow the noninvasive assessment of atherosclerotic
plaque characteristics (130) .
Intracoronary ultrasound and intracoronary Doppler
measurements will also allow further study of the mechani-
cal factors that determine the extent of thrombus formation
after plaque rupture . It is knuwn that the delivery of platelets
to the vascular wall is dependent on shear forces (131,132),
and such measurements may shed light on the mechanical
factors that determine whether a ruptured plaque results in a
completely or partially occluding thrombus . Angiographic
studies thus far have been unable to differentiate the culprit
lesions in unstable angina from those producing myocardial
infarction (10) .
Pharmacologic Interventions . Once vulnerable plaque is
identified, hypolipidemic therapy, beta-blockers and, possi-
bly, angiotensin-converting enzyme inhibitors and antioxi-
dants can be used to reduce the incidence of plaque rupture .
Very minimal regression of atherosclerosis has been shown
to substantially reduce the incidence of myocardial infarc-
tion, unstable angina and cardiac death (Table 3) (12-
19,133). Presumably, this is because of a lowered incidence
of plaque rupture. Reduction of plasma lipids (LDL) reduces
the amount of cholesterol entering the plaque and probably
allows cholesterol clearance from the plaque by HDL (134) .
The Helsinki Heart Study (135) showed that increasing
serum HDL with gemifibrozil decreases cardiac mortality .
The Program on the Surgical Control of Hyperlipidemias
trial (18) demonstrated a 33% reduction in cardiac death and
nonfatal myocardial infarction after a 23 .3% reduction in
total serum cholesterol . The Familial Atherosclerosis Treat-
ment Study (13), which produced only a 1% mean regression
of coronary artery stenoses with colestipol and lovastatin or
niacin, showed a striking 73% reduction in cardiovascular
events. The reduction in cardiac events in these trials was
remarkable and at large variance with the small amount of
regression produced (Table 3) . Removal of lipid increases
the plaque's relative collagen content and increases the,
production of heavily cross-linked collagen resistant to
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ruptures. These silent "miniruptures" may play an impor-
tant role in the progression of atherosclerosis .
Angiotensin-converting enzyme inhibitors . Recent evi-
dence from trials of angiotensin converting enzyme inhibi-
tors in patients with ischemic heart disease points to a
reduced incidence of ischemic cardiac events (Table 4) .
Angiotensin H may play a role in the initiation of plaque
rupture . Constantinides (44,137) showed that the infusion of
angiotensin into the coronary arteries of hyperlipidemic
rabbits can produce endothelial damage and can induce
plaque rupture . Genetic studies have shown that the angio-
tensin-converting enzyme inhibitor genotype DD, which is
associated with high circulating levels of angiotensin-
converting enzyme inhibitors, is more frequent in survivors
of myocardial infarction than in control subjects (138) . The
recent Survival and Ventricular Enlargement trial (139) was
designed to assess the effects of captopril in patients with left
ventricular dysfunction after myocardial infarction . Analysis
of the rates of myocardial infarction over the 36-month
follow-up period showed a 25% reduction (p = 0 .015) in the
incidence of reinfarction in those patients receiving capto-
pril . The Studies of Left Ventricular Dysfunction (SOLVD)
trial (140) showed a trend to a reduced (28% risk reduction,
p < 0.07) incidence of myocardial infarction in patients with
heart failure treated with enalapril . This trend was also seen
in the SOLVD prevention trial (141) . The mechanism of any
possible reduction in the incidence of plaque rupture by
angiotensin-converting enzyme inhibitors is uncertain . It
may be due to a reduction in arterial wall stress caused by
lower blood pressure or reduced levels of neurohumoral
activation (142), or their effect on protein synthesis influenc-
ing plaque composition . Angiotensin 11 is a growth factor for
vascular smooth muscle cells (143,144) . The inhibition of this
and other growth factors may modify plaque composition in
such a way that the likelihood of plaque rupture is reduced .
Further research into the role of angiotensin lI in atherogen-
esis and the mechanism of any possible benefit of angioten-
sin-converting enzyme inhibitors on plaque stability is re-
quired. Such research is inhibited by the lack of a suitable
animal model of plaque rupture .
Beta-blockers. There is a great deal of evidence that
beta-blockers reduce the incidence of plaque rupture . Nu-
merous secondary prevention trials with beta-blockers have
shown a reduced incidence of reinfarction and death (145-
148). Meta-analysis of these secondary prevention trials has
shown a 20% reduction in cardiac mortality, an additional
25% reduction in the incidence of reinfarction and a 30%
reduction in the incidence of sudden death (148) . Beta-
blockade reduces the circumferential plaque stress (149) by
reducing blood pressure and blunting hypertensive pressure
surges
. Beta-blockers may also prevent plaque rupture by
breakdown (136), resulting in plaque "strutting" and in-
increasing the ability of the plaque's fibrous cap to withstand
creased stability. These trials also demonstrated that pa-
stress. The stress-bearing abilities of plaque vary with the
tients receiving lipid-lowering therapy had less plaque pro-
frequency of the applied stress (107)
. Because plaque stiff-
gression than that of control patients . Regression therapy
ness increases with heart rate, beta-blockers may increase
may also reduce the incidence of asymptomatic plaque
	
plaque tensile strength by reducing heart rate (149)
.
Figure 7. Intravascular ultrasound images of the culprit coronary
lesions in patients with stable angina (A) and unstable angina (B) .
The ruptured plaque (B) has a thin fibrous cap (black arrows)
and
thick lipid pool (white arrows) compared with the stable plaque (A) .
Ultrasound images courtesy of Steven Nissen, MD .
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Table 3
. Regression of Coronary Atherosclerosis by Aggressive Lipid-Lowering Therapy and Effect on Incidence of
Myocardial Infarction
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(1/26 vs. 10128)
"Cannot be calculated . CLAS
- Cholesterol Lowering Atherosclerosis Study; FATS
= Familial Atherosclerosis Treatment Study ; NHLBI = National Heart,
Lung, and Blood Institute Type 11 Coronary Intervention Study
; POSCH = Program on the Surgical Control or Hyperlipidemia; STARS
= St Thomas'
Atherosclerosis Regression Study .
Antioxidants. Antioxidants may also prevent plaque rup-
ture. Oxidized LDL is an initiator of macrophage accumu-
lation within the plaque. If a plaque's macrophage content is
reduced, then the secretion of collagen-weakening proteases
may be reduced . This, theoretically, can be achieved by
antioxidants, which limit the formation of oxidized LDL
(150-152) . It has been shown that the lipid-lowering antiox-
idant agent probucol reduces atherosclerosis in animal mod-
els to a greater degree than expected by its lipid-lowering
action: alone (153) . Other antioxidants, including vitamin E,
beta-carrotene, vitamin C and selenium, may also alter the
course of atherosclerosis by preventing the oxidation of
LDL (154), However, the effect of these agents on the
incidence of plaque rupture has not been studied.
Modification of the fibrinolytieleoagulatton system .
Modification of the fibrinolytic and coagulation systems will
alter the consequences of plaque rupture. Aspirin reduces
Table 4. Effect of Angiotensin-Converting Enzyme Inhibitors on Incidence of
Myocardial Infarction
EF = yection fraction; MI = myocardial infarction ; SAVE = Survival and Ventricular Enlargement trial ;
SOLVD = Studies of Left Ventricular Dysrunction trial .
the incidence of myocardial infarction in asymptomatic men
(155) and reduces the rate of myocardial infarction in pa-
tients with chronic stable angina by 87% (156) . A meta-
analysis of aspirin in secondary prevention trials after myo-
cardial infarction showed a 31% reduction in nonfatal
reinfarctions and a 13% reduction in mortality due to vascu-
lar causes (157). Although there is some evidence that
aspirin inhibits the formation of new coronary lesions, it
does not appear to prevent progression of established coro-
nary lesions (155,158) . Aspirin inhibits platelet production of
thromboxane A
2
and therefore prevents platelet aggregation
and coronary artery vasospasm (60,155) . The reduction in
the incidence of myocardial infarction and cardiovascular
death by aspirin is due to the inhibition of thrombus forma-
tion after plaque rupture has occurred . Coronary thrombus
formation has also been inhibited by monoclonal antibodies
and competitive antagonists of the platelet membrane glyco-
Study
Turapy Regression
Cardiac Events
(treated vs . control
subjects)
% Event
Reduction
Combined: Drug
Colestipol ± niacin *_ 2% Mean stenosis reduction 0% vs . 3%
a
Regimen Trial (12) lovastatin
(0140 vs. 1/32)
FATS (13)
Colestipol + lovastatin 1% Mean stenosis reduction 7% vs . 19% 65%
Lifestyle Heart Trial (14)
or niacin
Strict diet; life style
modification
2% Mean stenosis reduction
(3146 vs. 10/52)
Not reported
w
NHLBI 11(16)
Cholestyramine 6.9% of patients
11% vs. 16% 33%
(8/71 vs. 12!72)
CLAS (13) Colestipol + niacin
18% of patients 1% vs . 4% 75%
(1/94 vs. 4/94)
CLAS 11(17) Colestipol + niacin
18% of patients 24% vs. 34% 43%
(18175 vs . 22/63)
POSCH (18) Partial illeal bypass
14!1, of patients 22% vs. 33% 26%
(91/421 vs. 1381417)
STARS (diet) (19) Diet
38% of patients 11% vs. 36% 69%
(3/27 vs. 10128)
STARS (treatment) (19) Diet
+ cholestyramine 33% of patients 4% vs . 36:8 89%
Trial Inclusion Criteria Agent
Incidence of Ml
Treated vs.
Control Subjects
% Reduction
in MI
SAVE (139) Post-MI, EF < 40% Captopril 13311,115 vs . 25 (p = 0.615)
170/I ,116
SOLVD (140) Chronic heart failure, Enalapril 4001,284 vs. 531 28 (p < 0.07)
EF < 35% 1,285
14SOLVD Prevention EF < 35%, no treatment Enalapril 4612,117 vs. 521
Trial (t41) 2,117
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protein IIb1IIla receptor, the final common pathway of
platelet aggregation (159,160). The imminent investigational
availability of an orally active glycoprotein llb/Illa receptor-
antagonist for long-term administration may provide a much
more potent inhibition of coronary platelet activation and
thrombus formation .
If the activity of the native fibrinolytic system could be
increased, then the extent of thrombus formation after
plaque rupture could be reduced . Several agents, such as
stanozolol and ethyloestrenol, enhance the endogenous fi-
brinolytie system via downregulation of plasminogen activa-
tor inhibitor. However, the side effects of these drugs have
prevented the study of their effect on the incidence of acute
ischemic syndromes (161). New drugs may overcome these
difficulties .
Application of molecular biology. The determinants of
plaque composition are poorly understood. The factors that
influence the relative lipid and structural protein content of
mature plaque have not been addressed. Although the lipid
content of a plaque may simply reflect plasma cholesterol
levels, many local factors, such as cytokine secretion,
plaque cellular content, plaque blood supply and the me-
chanical force acting on the plaque, may also influence tht .
macrophage and lipid content of plaque . The detection of the
cytokines that mediate macrophage recruitment and influ-
ence smooth muscle cell collagen secretion will allow the
local application of inhibitors such as gamma-interferon
(162) to prevent these processes. Although proteases have
been detected within atherosclerotic plaques (110,111), com-
parative quantification between stable and ruptured plaques
has not been performed . Further investigation of the stimuli
of macrophage protease production and, in particular, the
role of oxidized LDL and lipoprotein (a) are clearly war-
ranted.
Recently, a landmark experiment by Simons et al . (163)
reported that the local application of an antisense oligonu-
cleotide toc-myb proto-oncogene suppresses smooth muscle
cell intintal proliferation after rat carotid artery injury . This
combined the two emerging fronts underpinning the future of
coronary intervention: site-specific delivery and the modu-
lation of the genetic regulators of intimal proliferation . If the
differences in gene expression between ruptured and stable
plaques can be demonstrated, antisense oligonucleotides
could be developed to stabilize plaque . In particular, the
nuclear transcription factor NF-1cB is emerging as a common
pathway for leukocyte activation and therefore for monocyte
recruitment into plaque (164,165) . The development of dual
(166), perforated (167) and coated (168) angioplasty balloons
and polymer stents (169) may allow the local delivery of
genetic therapies to vulnerable plaque .
Summary
The rupture of lipid-laden, macrophage-rich plaques ini-
tiates the development of acute cardiac ischemic syndromes .
These plaques are vulnerable to rupture because of their low
Intravascular
Ultrasound
Site
Specific
Treatment
t
Idemlify Basic Fibrinolytic Defect
.
Improved Platelet Inhibition
Figure S. Once vulnerable atheroscletotic plaque is identified,
plaque can potentially be rendered quiescent by the application of
pharmacologic therapies, modification of platelet activity and de-
fects in the fibrinolytic system and the site-specific application of
advances in cardiovascular molecular biology,
tensile strength and the concentration of mechanical stress at
their edges. There is recent evidence that the incidence of
plaque rupture can be substantially reduced. This opens up
the possibility of a preventative approach to the management
of established coronary atherosclerosis . The convergence of
five frontiers of cardiovascular research-intravascular ul-
trasound, pharmacologic intervention, modification of the
fibrinolytic/coagulation system, molecular and cellular biol-
ogy of atherosclerosis and site-specific treatment-will en-
able the stability of atherosclerotic plaques to be assessed
and modified (Fig . 8) . Systemic and local therapy can theft be
used to increase plaque tensile strength and reduce the
mechanical forces exerted on the plaque . Modification of the
coagulation and fibrinolytic system can limit the extent of
coronary thrombosis . Such an approach should lead to a
much higher order prevention of unstable angina, acute
myocardial infarction and sudden cardiac death in the future
by rendering coronary atherosclerotic plaque quiescent.
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